The c-MYB oncogene plays a key role in hematopoietic cell differentiation and proliferation. Genetic abnormalities and dysregulation of MYB have been found in several cancers, including adenoid cystic carcinoma (ACC) (80% of cases), making it an attractive druggable target for ACC treatment.
The c-MYB oncogene plays an important role in hematopoietic cell differentiation and proliferation. Dysregulation of MYB downstream effector signaling is thought to be behind these abnormalities by modulation of genes such as BCL2, MYC or FLT3, and as such an attractive therapeutic target for acute myeloid leukemia (AML).
Remix Therapeutics Inc. has closed a $60 million financing to advance its lead program, REM-422, into the clinic and for further advancement of a pipeline of RNA processing targeted therapeutics.
With its launch barely three years in the rearview mirror, Remix Therapeutics Inc. has inked its second potential $1 billion pharma collaboration, drawing Roche Holding AG to the table with the promise of its RNA processing platform and the potential to develop small-molecule therapeutics targeting the underlying drivers of disease. At the same time, the Watertown, Mass.-based firm added $60 million in a venture round, bringing its total financing to date to $201 million.
MYB is a transcription factor essential for cell proliferation and differentiation, and is regarded as a target for cancer therapy because it is overexpressed in many different tumor types such as adenoid cystic carcinoma (ACC), acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia, among others.
